Experience of the Patient Treated With Trastuzumab (Herceptin ®) as Adjuvant for Breast Cancer: Fatigue and Quality of Life During and Waning of Treatment, Psychosocial Aspects (Environment, Work)
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label
score of fatigue
The main objective of this study is to evaluate the score of fatigue in patients with HER2 overexpressing breast cancer and for whom Herceptin ® treatment is prescribed, compared with a population of patients treated with the same age the same chemotherapy without Herceptin ®.
at 9 months
Corinne DELCAMBRE, MD
Centre François Baclesse
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)